159sek
-40,1 %
Date:2024-05-03Time:10:37:57Latest report:Q4-2023List:First NorthTicker:EXPRS2
Market Cap:80 msekEnterprise Value:22 msekNet Sales:7,05 msekEarnings:-96,0 msekEmployees:0ISIN:SE0008348262

Ratios

10-year key figure history for ExpreS2ion Biotech turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for ExpreS2ion Biotech with index and moving average MA50 and MA200.

Stockprice:1,59
MA50:2,55
MA200:2,36
Price/MA200:-34,3 %
RSI (14):31,4
Price/MA50:-39,2 %

Description

ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

Biotechnology